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a  b  s  t  r  a  c  t
AS1411  is  a G-rich  aptamer  that forms  a stable  G-quadruplex  structure  and  displays  antineoplastic  prop-
erties both  in vitro  and  in vivo.  This  oligonucleotide  has  undergone  phase  2 clinical  trials.  The  major
molecular  target  of AS1411  is nucleolin  (NCL),  a multifunctional  nucleolar  protein  also  present  in the
cell  membrane  where  it selectively  mediates  the  binding  and  uptake  of  AS1411.  Cell-surface  NCL  has
been  recognised  as  a low-afﬁnity  co-receptor  for human  immunodeﬁciency  virus  type  1 (HIV-1)  anchor-
age on  target  cells.  Here  we  assessed  the anti-HIV-1  properties  and  underlying  mechanism  of  action  of
AS1411.  The  antiviral  activity  of  AS1411  was  determined  towards  different  HIV-1  strains,  host  cells  and
at  various  times  post-infection.  Acutely,  persistently  and latently  infected  cells  were  tested,  including
HIV-1-infected  peripheral  blood  mononuclear  cells  from  a healthy  donor.  Mechanistic  studies  to  exclude
modes  of  action  other  than  virus  binding  via  NCL were  performed.  AS1411  efﬁciently  inhibited  HIV-1
attachment/entry  into  the  host  cell.  The  aptamer  displayed  antiviral  activity  in  the  absence  of cytotoxic-
ity at  the  tested  doses,  therefore  displaying  a wide  therapeutic  window  and  favourable  selectivity  indexes.
These ﬁndings,  besides  validating  cell-surface-expressed  NCL as an  antiviral  target,  open  the  way  for the
possible  use  of AS1411  as  a new  potent  and  promisingly  safe  anti-HIV-1  agent.
©  2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license. Introduction
G-quadruplexes are guanine (G)-rich oligonucleotides capable
f forming four-stranded structures. Among G-quadruplex-
orming G-rich oligonucleotides, the aptamer AS1411 has stood
ut for its improved biological activity. AS1411 was described in
he late 1990s [1] and was later developed as an anticancer agent.
he mechanism of action of AS1411 has been ascribed to its bind-
ng to the multifunctional cellular protein nucleolin (NCL). NCL is
verexpressed on cancer cell membranes and mediates AS1411 cel-
ular uptake [2]; in turn, selective binding between AS1411 and
CL affects intracellular NCL-dependent pathways, resulting in the
iological effects of AS1411 [2–5].AS1411 has now completed two phase 2 clinical trials. The
esults were encouraging with regard to toxicity since the aptamer
as very well tolerated with no severe adverse events related to
∗ Corresponding author. Tel.: +39 049 827 2346.
E-mail address: sara.richter@unipd.it (S.N. Richter).
ttp://dx.doi.org/10.1016/j.ijantimicag.2016.01.016
924-8579/© 2016 The Authors. Published by Elsevier B.V. This is an open access article u(http://creativecommons.org/licenses/by/4.0/).
drug administration. However, the anticancer activity was  limited
to one patient; the basis for such activity is currently under inves-
tigation [6].
Interestingly, NCL is involved in the very initial step of human
immunodeﬁciency virus type 1 (HIV-1) virion–cell recognition,
referred to as attachment. HIV-1 attachment can occur in the
absence of the main cellular receptors, i.e. CD4 and CXCR4/CCR5,
through co-ordinated interactions with heparan sulfate proteogly-
cans and cell-surface-expressed NCL [7]. NCL was found in cellular
fractions containing the HIV genome, viral matrix and reverse
transcriptase as well as in cross-linked complexes with CD4  and
CXCR4/CCR5 at the cell membrane, supporting its potential role
in viral entry [8,9]. Cell-surface NCL is markedly downregulated
immediately after HIV entry into permissive cells as a conse-
quence of its translocation into the cytoplasm [8]. Moreover, NCL is
involved in speciﬁc HIV-associated cell cycle perturbations since
lymphocytes isolated from HIV-infected patients displayed NCL
hyperlocalisation on the cell surface [10]; in patients treated with
antiretroviral therapy this effect was also observed in HIV-infected
subjects with poor immunological recovery [11]. Thereafter, cell
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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urface NCL has been proposed as an anti-HIV-1 target: a pen-
americ pseudopeptide [8] and natural NCL ligands located in the
ell membrane [12–14] indeed inhibited HIV replication by block-
ng virus attachment to the cell surface. In the recent years, cell
embrane molecules such as chemokine co-receptors CXCR4 and
CR5 have emerged as attractive therapeutic targets for anti-HIV-1
herapy since the use of speciﬁc antagonists efﬁciently blocked the
IV-1 entry process. For example, the CCR5 antagonist maraviroc
as been approved by the US Food and Drug Administration (FDA)
o treat HIV-1-infected persons and has proved extremely effective
15].
Based on the above information, the aim of this study was to
est whether the aptamer AS1411 was able to interfere with HIV-
 cellular entry. An indication of the antiviral activity of AS1411
as recently been provided [16]. Here we aimed at testing AS1411
gainst different viral strains, cell lines and primary cells and inves-
igating the most relevant mechanism of action.
. Materials and methods
.1. Oligonucleotides and compounds
Oligonucleotides (Supplementary Table S1), dextran sulfate
000 (DS 8000) and AMD3100 were purchased from Sigma-Aldrich
Milan, Italy), nevirapine was from Boehringer Ingelheim (Ridge-
eld, CN) and enfuvirtide (Fuzeon®) was from Roche (Vilvoorde,
elgium). Zidovudine (AZT) was synthesised by one of the authors
CP).
Supplementary Table S1 related to this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.ijantimicag.2016.
1.016.
.2. Virus stocks
HIV-1NL4-3 and HIV-1BaL stocks were prepared by transfection of
EK 293T with proviral genomes (NIH AIDS Research and Reference
eagent Program). The HIV-1IIIB stock was originally provided by
rof. R.C. Gallo and Dr M.  Popovic.
.3. Antiviral assay
The TZM-bl reporter cell line (NIH AIDS Research and Reference
eagent Programme) was seeded in 96-well plates (Falcon®; Corn-
ng Life Sciences, Durham, NC), was infected with HIV-1NL4-3 or
IV-1BaL at different multiplicities of infection (MOIs) (0.05, 0.1 and
.5) and was treated with serial dilutions of test oligonucleotides.
fter 24–72 h, HIV-1 production was assessed following the long
erminal repeat (LTR) luciferase signal using the briteliteTM plus
eporter Gene Assay System (Perkin Elmer, Waltham, MA)  accord-
ng to the manufacturer’s protocol.
MT-4 cells (NIH AIDS Research and Reference Reagent Pro-
ram) were seeded in 96-well plates in the presence of HIV-1NL4-3
t different MOIs (0.003, 0.05, 0.1 and 0.5) and serial dilu-
ions of AS1411 or CRO26. After 24–120 h, HIV-1 production was
etermined by measuring p24 antigen concentration in the super-
atant using an HIV-1 p24 ELISA assay (XpressBio, Thurmont,
D). Sample absorbance at 450 nm was measured using a Tecan
unriseTM Microplate Reader (Tecan, Cernusco sul Naviglio, Italy).
he cytotoxicity of test oligonucleotides in TZM-bl and MT-4
ells was tested using the MTT  [(3-(4,5-dimethylthiazol-2-yl)-2,5-
iphenyltetrazolium bromide) tetrazolium] assay.
Peripheral blood mononuclear cells (PBMCs) were activated
or 48 h with phytohaemagglutinin (2.5 g/mL) and interleukin-
 (IL-2) (10 ng/mL) and were washed and cultured in complete
PMI-1640 and IL-2 (10 ng/mL). Activated PBMCs were infected
or 2 h with HIVIIIB (using 5.5 ng equivalent of p24 per 105 cells)timicrobial Agents 47 (2016) 311–316
and were untreated or treated with AS1411, CRO26, AMD3100
or enfuvirtide. AS1411 and CRO26 were replenished every 28 h.
Aliquots of supernatants were obtained at Days 4, 6, 8 and 10
post-infection (p.i.) and p24 was measured. At Day 10 p.i., cells
were counted using trypan blue exclusion to assess viability, and
MTS  [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium] assays were performed to
evaluate cell metabolism.
2.4. Antiviral assay in chronically HIV-1-infected cells
HuT78/IIIB cells are HuT78 cells persistently infected with the
HIV-1IIIB strain. The antiviral activities of test aptamers against per-
sistent HIV-1 infection were based on inhibition of p24 antigen
production in Hut78/IIIB cells pre-treated with AZT (10 ng/mL). Pre-
treated HuT78/IIIB cells were seeded in a 48-well plate (Costar®;
Corning Inc., Corning, NY) in the presence of serial dilutions of
AS1411 or CRO26. After 43 h, supernatants were collected and
HIV-1 production was determined by measuring p24 antigen. The
cytotoxicity of test aptamers on HuT78/IIIB cells was tested in par-
allel by MTT  assay.
2.5. Antiviral assay in latently infected cells
OM10.1 (NIH AIDS Research and Reference Reagent Program)
is a promyelocytic HIV-1 latently infected HL-60 cell line. The
antiviral activity of test aptamers was based on inhibition of
p24 antigen production in OM10.1 cells pre-treated with AZT
(10 ng/mL) and stimulated with phorbol-12-myristate-13-acetate
(PMA) (0.02 M).  Cells were seeded in a 48-well plate in the pres-
ence of serial dilutions of AS1411 or CRO26. After 48 h, supernatants
were collected and HIV-1 production was  determined by measur-
ing p24 antigen as previously described. The cytotoxicity of test
aptamers on OM10.1 cells was  assessed in parallel using the MTT
assay.
2.6. Viral binding assay
MT-4 cells were incubated with serial dilutions of test aptamers,
DS 8000 or AMD3100 and then HIV-1IIIB stock dilutions (cor-
responding to 100 ng of p24) were added. After 2 h at 37 ◦C,
cells were washed to remove unbound viral particles and were
subsequently lysed with 1× phosphate-buffered saline (PBS) con-
taining 0.5% Tergitol® NP-40 (Sigma, St Louis, MO). The amount
of p24 antigen in the cell lysate was  measured as described
above.
2.7. Time-of-addition assay
MT-4 cells were infected with HIV-1IIIB at a MOI  of 0.5. After
1 h, cells were washed, seeded and incubated at 37 ◦C. AS1411 and
the reference compounds DS 8000, AMD3100, enfuvirtide, AZT and
nevirapine were added at different time points p.i. AS1411 was
added at 25 M and the reference compounds were added at a
concentration corresponding to 100-fold their 50% inhibitory con-
centration (IC50). HIV-1 production was  determined 31 h p.i. by
measuring p24 antigen in the supernatant.
2.8. Surface plasmon resonance (SPR)-directed afﬁnity binding
analysisSPR experiments were performed on a BiacoreTM T100 plat-
form (GE Healthcare Europe, Milan, Italy). The human recombinant
protein NCL (OriGene Technologies Inc., Rockville, MD)  and the
HIV-1IIIB recombinant gp120 (ImmunoDiagnostics Inc., Woburn,
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Table  1
Anti-HIV-1 activity and cytotoxicity of the G-quadruplex-forming aptamer AS1411.
Hours p.i. Cell line Virus Strain Tropism Type of infection IC50 (nM)a CC50 (nM)b SIc Administration times
24 TZM-bl HIV-1 NL4-3 X4 tropic Ex novo 13.7 ± 1.7 >25 000 >1825 1
MT-4  HIV-1 NL4-3 X4 tropic Ex novo 16.2 ± 4.3 >25 000 >1543 1
TZM-bl HIV-1 BaL R5 tropic Ex novo 19.6 ± 3.8 >25 000 >1276 1
48 TZM-bl HIV-1 NL4-3 X4 tropic Ex novo 15.3 ± 1.9 >25 000 >1634 1
MT-4  HIV-1 NL4-3 X4 tropic Ex novo 23.7 ± 3.7 >25 000 >1055 1
TZM-bl HIV-1 BaL R5 tropic Ex novo 36.5 ± 3.0 >25 000 >685 1
72 TZM-bl HIV-1 NL4-3 X4 tropic Ex novo 22.3 ± 3.0 >25 000 >1121 1
MT-4  HIV-1 NL4-3 X4 tropic Ex novo 105.3 ± 16.9 >25 000 >237 1
TZM-bl HIV-1 BaL R5 tropic Ex novo 45.4 ± 5.2 >25 000 >551 1
120 MT-4 HIV-1 NL4-3 X4 tropic Ex novo 1490.9 ± 50.1 >5000 >3 1
MT-4  HIV-1 NL4-3 X4 tropic Ex novo 405.7 ± 19.0 >5000 >12 4
–  HuT78/IIIB HIV-1 IIIB X4 tropic Persistent >25 000 >25 000 – 1
–  OM10.1 HIV-1 LAI X4 tropic Latent >25 000 >25 000 – 1













































viral binding up to 45% only at the highest tested concentration ofuciferase signal (TZM-bl) or p24 antigen production (MT-4).
b 50% cytotoxic concentration, deﬁned as the concentration of the oligonucleotid
c The selectivity index (SI) is the relative effectiveness of the tested aptamer in in
A)  were immobilised on a Series S Sensor Chip CM5  (GE Health-
are Europe) by amine coupling in HEPES-NaCl running buffer.
CL and gp120 were diluted in sodium acetate buffer at 15 ng/L
nd 20 ng/L, respectively, and were injected to reach 1500 res-
nance units (RU). Binding analysis was performed at 20 L/min
ith contact and dissociation times of 120 s in HEPES-KCl buffer.
est oligonucleotides (Supplementary Table S1) were diluted to
 M in HEPES-KCl buffer, were denatured at 95 ◦C for 5 min  and
ere cooled at room temperature. Sensorgrams were obtained in
he concentration range of 15.6–1000 nM.  The chip surface was
egenerated with 1 M KCl solution. All sensorgrams were corrected
y subtraction of blank ﬂow cell response and buffer injection
esponse.
. Results
.1. The AS1411 aptamer has potent anti-HIV-1 activity against
ifferent strains in cell lines and primary cells
Based on the known role of NCL in HIV attachment, we inves-
igated whether AS1411 was able to inhibit HIV-1 replication by
locking its attachment/entry into the host cell through interac-
ion with cell-surface NCL. The antiviral activity of AS1411 was
nitially assessed in TMZ-bl and MT-4 cell lines, which were infected
ith X4/R5-tropic HIV-1 strains at different MOIs (0.003, 0.05, 0.1
nd 0.5) and were incubated in the presence of serial dilutions of
S1411 or the negative control CRO26. Virus amount in the super-
atant was assessed at different time points p.i. (24, 48, 72 and 120 h
.i.) through quantiﬁcation of the luciferase signal (TZM-bl) or p24
iral protein (MT-4). The cytotoxicity of AS1411 and CRO26 was
ssessed in parallel using the MTT  assay. AS1411 markedly reduced
irus production in all tested conditions (Table 1), whilst CRO26 did
ot show any antiviral effect (Supplementary Table S2). A slight
ecrease in the antiretroviral activity of AS1411 was observed at
ncreasing times p.i. (i.e. 72 h and 120 h p.i.). Because the aptamer
as administrated only once at the time of infection, we  hypothe-
ised that reduction of compound effectiveness [17] was  the main
ause of the decreased antiviral activity at long test times. To test
his hypothesis, AS1411 was administered at 24-h intervals for four
imes in infected MT-4 cells and virus production was measured
t 120 h p.i. An increase in AS1411 efﬁcacy was indeed observed
ompared with the single administration of the aptamer (Table 1).
otably, AS1411 had no cytotoxicity up to the highest tested con-
entration, yielding high selectivity indexes of >500 under most
ested conditions.ired to reduce cell proliferation by 50%.
ng viral replication compared with inducing cell death (CC50/IC50).
Supplementary Table S2 related to this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.ijantimicag.2016.
01.016.
AS1411 was next evaluated in freshly isolated PBMCs, a nat-
ural target during in vivo infection. When PBMCs were infected
with HIV-1IIIB, AS1411 inhibited viral production by ca. 64% and
97% at 500 nM and 5 M,  respectively, at 4 days p.i. (Fig. 1A). Con-
sistent with previous results, a decrease in activity was  observed
at increasing times p.i. However, at 10 days p.i. and 5 M,  AS1411
retained signiﬁcant antiviral activity with 80% inhibition of viral
production (Fig. 1A) and prevented viral-induced cell death as
shown by the MTS  assay (Fig. 1B). Similar results were obtained
with the reference HIV-1 entry inhibitors enfuvirtide and AMD3100
(Fig. 1A, B). These data indicate that the antiviral activity of AS1411
is relevant to primary infected cells.
To assess the mechanism of action of AS1411, two  infected cell
models sensitive to drugs acting during post-integration steps were
investigated. OM-10.1 cells are latently HIV-1-infected promyelo-
cytes containing a single integrated provirus; they sustain latent
HIV-1 infection under normal culture conditions. HIV-1 produc-
tion is induced by phorbol esters (e.g. PMA). HuT78/IIIB cells are
HIV-1IIIB-persistently infected HuT78 cells stably producing infec-
tious viral particles. AZT pre-treatment of HuT78/IIIB cells allows
the evaluation of post-integration effects. In both setups, treatment
with AS1411 did not produce antiviral effects as measured by p24
antigen production (Table 1), indicating that no post-integration
events were affected by AS1411.
The viral step targeted by AS1411 was  investigated by a time-
of-addition assay. After infection, AS1411 and control compounds
were added each hour over 8 h and at 24–25 h p.i. and virus repli-
cation was monitored by p24 expression at 31 h p.i. AS1411 had
to be added at the time of infection (0 h p.i.) to observe inhibitory
activity on virus production. This behaviour was shared with the
attachment inhibitor DS 8000 and was similar to that of the CXCR4
co-receptor antagonist AMD3100 (Fig. 1C). In contrast, the fusion
inhibitor enfuvirtide maintained activity when added up to 30 min
after infection. These data suggest that AS1411 inhibits adsorption
of the virus to the host cell. This mechanism of action was conﬁrmed
by a viral binding assay. AS1411 was  able to block viral binding by
65% with respect to the untreated control with an IC50 value lower
than 400 nM,  whilst the control oligonucleotide CRO26 inhibited50 M,  probably owing to a reported general mechanism of viral
entry inhibition due to an unspeciﬁc mechanism of electrostatic
interaction with the viral/cell surface [18] (Fig. 1D). Both DS 8000
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Fig. 1. Inhibition of a human immunodeﬁciency virus type 1 (HIV-1) early step by AS1411. (A) Antiviral activity of AS1411 in HIV-1IIIB-infected peripheral blood mononuclear
cells  (PBMCs). Freshly isolated PBMCs were infected with HIV-1IIIB and treated with test aptamer or reference compounds. Virus-associated p24 antigen was measured at Days
4,  6, 8 and 10 post-infection (p.i.). (B) Cell viability evaluated via MTS assay at 10 days p.i. in HIV-1IIIB-infected PBMCs and treated with AS1411 or reference compounds. (C)
Time-of-addition assay. MT-4 cells were infected with HIV-1IIIB and test aptamer or reference compounds were added at different time points after infection. Virus-associated
p24  antigen in the supernatant was measured 31 h p.i. The antiviral activity of AS1411 was  compared with that of the negative control and with reference drugs. The data
are  representative of two  independent experiments. (D) Viral binding assay. Effect of AS1411 on HIV-1IIIB binding to MT-4 cells. Cells were incubated with HIV-1IIIB viral
particles in the presence or absence of different concentrations of AS1411 and were subsequently cleared from excess compound by washing steps. DS 8000 and AMD3100
were  tested in parallel as reference drugs. After lysis of the cells and eventually attached virus, the amount of virion-associated p24 was quantiﬁed and used to calculate the






aE)  or HIV-1IIIB gp120 (F). Experimental curves in red and ﬁtting curves in black. (Fo
he  web  version of this article.)
nd AMD3100 blocked virus binding up to 65% and 58%, respec-
ively, of the untreated control (Fig. 1D). The aptamer behaviour
as again superimposable to that of DS 8000, indicating that virus
ttachment is the main targeted step.rpretation of the references to colour in this ﬁgure legend, the reader is referred to
Some anti-HIV-1 G-quadruplex (G4)-forming aptamers have
been reported to bind the HIV-1 gp120 envelope glycoprotein,
blocking virus attachment [18]. We  thus investigated whether
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PR. We also tested a HIV-1 G4-forming oligonucleotide (LTR-III)
19], a G-rich non-G4-forming scrambled oligonucleotide (SCRA)
nd the C-rich sequence CRO26. Although some G4 structures
ave been reported to bind gp120 [20], the binding to gp120 of
oth AS1411 and LTR-III was too low to obtain meaningful bind-
ng afﬁnity constants (Fig. 1F; Supplementary Fig. S1B). The other
equences did not bind as well (Supplementary Fig. S1D, F). Bind-
ng to NCL was next assessed for comparison. AS1411 showed a
ose-dependent interaction with NCL (KD = 34.2 nM)  with fast asso-
iation rates (Fig. 1E); in this setting, LTR-III showed lower binding
fﬁnity to NCL (KD = 76.3 nM)  and slower association rates com-
ared with AS1411 (Supplementary Fig. S1A). In contrast, SCRA and
RO26 exhibited very low binding to NCL and no KD could be calcu-
ated in these conditions (Supplementary Fig. S1C, E). The antiviral
ctivity of LTR-III was also assessed and was ca. 40 times lower than
hat of AS1411, whereas SCRA was inactive (Supplementary Table
2). These data support that binding to NCL is the main mechanism
f action of AS1411: the peculiar binding mode of AS1411, due to
ts dimeric nature, high stability and natural propensity to fold into
4, may  account for the improved antiviral activity compared with
ther G4-forming oligonucleotides.
Supplementary Fig. S1 related to this article can be found, in the
nline version, at http://dx.doi.org/10.1016/j.ijantimicag.2016.01.
16.
. Discussion
Aptamers, short oligonucleotides that adopt speciﬁc three-
imensional structures in vivo, are able to bind with high afﬁn-
ty to target biomolecules and elicit a biological response. Their
inding afﬁnities to the target are generally similar to those of anti-
odies. However, unlike antibodies, they are extremely stable over
emperature, with solvent exposure and in harsh environments;
hey lack immunogenicity; and they display low interbatch vari-
bility. Owing to their small size they penetrate tissues fast and
re rapidly cleared from the blood. With these attractive features,
ptamers have been intensely investigated as therapeutics. One
ptamer (Macugen) has reached the clinic for the treatment of
ge-related macular degeneration by targeting vascular endothe-
ial growth factor. Five other aptamers, among which is AS1411,
ave been tested in phase 2 clinical trials [21]. In the HIV ﬁeld,
ost aptamers have been tested against viral proteins (i.e. gp120,
everse transcriptase, integrase) but none proceeded to advanced
linical trials [20,22–25], likely due to target mutations or phar-
acokinetic limits, shared by all aptamers. Interestingly, the G4
olding of AS1411 makes it more resistant to endonucleases [26].
e and others have previously shown that the HIV-1 LTR promoter
orms a dynamic G4 structure [19,27] that can be targeted by G4
igands to block viral transcription [28,29]. Interaction of the LTR
4s with NCL also strongly inhibits transcription [30]. We  initially
ested AS1411 to investigate whether its reported sequestration of
ellular NCL could affect LTR activity. In contrast, we found that
S1411 signiﬁcantly inhibited virus attachment. The equally high
ctivity of the aptamer against X4- and R5-tropic HIV-1 strains indi-
ates that the effect is independent of the nature of the ‘classic’
o-receptors. The fact that AS1411 strongly binds NCL (SPR data),
ts reported binding and intracellular uptake of membrane NCL [1]
nd the evidence of NCL usage by HIV as a co-receptor [7] suggest
 mechanism mediated by AS1411 interference at NCL that blocks
irus attachment.
For the antiviral activity of AS1411, lower doses and fewer
dministrations are required than for the aptamer’s antineoplastic
ctivity [1,2,31,32], therefore showing a broad potential thera-
eutic window for antiviral purposes. Moreover, if the anticancer
ctivity of AS1411 is conﬁrmed, the recently reported acquisition of
[
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cancer features in HIV-1-infected cells during antiretroviral ther-
apy treatment [33] might also be targeted, with the fascinating
possibility to exploit the anticancer effects of AS1411 during HIV-1
treatment, for example in seropositive patients affected by AIDS-
related cancers.
5. Conclusions
We have shown that AS1411, a G4-forming oligonucleotide, has
the potential to block HIV-1 infection by binding to cell surface
NCL and interfering with HIV-1 cell attachment. Since AS1411 has
already shown mild toxicity in clinical trials, testing in humans as an
anti-HIV-1 agent with a new mechanism of action can be envisaged
in the near future.
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